Oral Treatment With SP-333, an Analog of Uroguanylin, Effectively Relieves Morphine and Methadone-Induced Constipation in Rats Through a Novel Mechanism Involving Activation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)

p=0.00358), p=0.03316) and GAD-7 (R=0.779,p= 0.00003) scores in constipated patients correlated strongly with SBS (Figure 1).Correlations between psychometric testing and SBS were not significant in controls, except for p=0.014).The prevalence of SBD in constipation was 52% compared to 14% in controls.No significant differences were found between HRAM parameters in constipated patients with and without a positive SBS (Table 1B).Unpaired T-tests confirmed PHQ-9 (p=0.038,CI 0.30-9.56),PHQ-15 (p=0.0004,3.39-10.85),GAD-7 (p=0.025,CI 0.66-9.22)and SBS (p=0.024,CI 2.58-34.01)scores differed between the constipated and control groups.Conclusions: Severity of SBD correlates with the severity of depression, somatization, and anxiety.Symptoms of SBD were present in more than 50% of patients with chronic constipation.Constipated patients had similar HRAM profiles and rates of dyssynergy regardless of SBS status.Cognitive behavioral therapy, physical therapy and desensitization may be therapeutic for this population.Table 1.